Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 45
Filter
1.
Heliyon ; 9(4): e15098, 2023 Apr.
Article in English | MEDLINE | ID: mdl-37123937

ABSTRACT

In this paper, we propose a novel multi-stream video classifier for infant needs detection. The proposed system is an ensemble-based system that combines several machine learning to improve the overall result of the state-of-the-art algorithms. It is a multi-stream in the sense that it combines the output predictions of both audio and images of infants from every single classifier employed in the system for a unified result. This produces better performance and results compared to the previous other research techniques, which relied on only one of these modalities. For training and testing the proposed system, from the Dunstan Baby Language video collection, we built three separate datasets for videos, images, and sounds encompassing the five primary infant needs that require predicting. These are: hunger, have wind, uncomfortable (require diaper change), wants to burp or tired, with a total of 3348 samples. We used four different ensemble algorithms for the best reachable performance. The proposed algorithm improves the overall accuracies of each single classifier from a low of 51% to a high of 99%. The proposed method also improves the accuracy of the classification process by about 9% compared to the state-of-the-art approaches, which was 90%.

2.
Anticancer Agents Med Chem ; 22(17): 2942-2955, 2022.
Article in English | MEDLINE | ID: mdl-35410622

ABSTRACT

The thiazolopyrimidine nucleus is a bioisosteric analog of purine and an important class of N-containing heterocycles. Thiazolopyrimidine scaffolds are considered a promising class of bioactive compounds that encompass diverse biological activities, such as antibacterial, antiviral, antifungal, anticancer, corticotrophin-releasing factor antagonists, anti-inflammatory, antituberculosis, and glutamic receptors antagonists. Despite the importance of thiazolopyrimidines from a pharmacological viewpoint, there is hardly a comprehensive review on this important heterocyclic nucleus. Throughout the years, those scaffolds have been studied extensively for its anticancer properties and several compounds were designed, synthesized, and evaluated for their anticancer effects with activity in the µM to nM range. However, there are hardly any reviews covering the anticancer effects of thiazolopyrimidines. In this review, an effort was made to compile literature covering the anticancer activity of thiazolopyrimidines reported in the last decade (2010-2020). Nearly thirty articles were reviewed and compounds with IC50 < 50 µM against at least 50% of the used cell lines were listed in this review. The best ten compounds (10a, 14b, 17g, 18, 25e, 25k, 34e, 41i, 49a and 49c) showing the best anticancer activity against the corresponding cell lines during the last 10 years are highlighted. By highlighting the most active compounds, this review article sheds light on the structural features associated with the strongest anticancer effects to provide guidance for future research aiming to develop anticancer molecules.


Subject(s)
Antineoplastic Agents , Thiazoles , Anti-Bacterial Agents/pharmacology , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Antiviral Agents/chemistry , Humans , Molecular Structure , Structure-Activity Relationship , Thiazoles/chemistry
3.
Eur J Pharm Sci ; 169: 106084, 2022 Feb 01.
Article in English | MEDLINE | ID: mdl-34856350

ABSTRACT

Corticotropin-releasing factor (CRF) is a 41-amino-acid neuropeptide secreted from the hypothalamus and is the main regulator of the hypothalamus-pituitary-adrenocortical (HPA) axis. CRF is the master hormone which modulates physiological and behavioral responses to stress. Many disorders including anxiety, depression, addictive disorders and others are related to over activation of the CRF system. This suggests that new molecules which can interfere with CRF binding to its receptors may be potential candidates for neuropsychiatric drugs to treat stress-related disorders. Previously, three series of pyrimidine and fused pyrimidine CRF1 receptor antagonists were synthesized by our group and specific binding assays, competitive binding studies and determination of the ability to antagonize the agonist-stimulated accumulation of cAMP (the second messenger for CRF receptors) were reported. In continuation of our efforts in this direction, in the current manuscript, we report the synthesis & biological evaluation of a new series of CRF1 receptor antagonists. Seven compounds showed promising binding affinity with the best two compounds (compounds 6 & 43) displaying a superior binding affinity to all of our previous compounds. Compounds 6 & 43 have only 4 times and 2 times less binding affinity than the standard CRF antagonist antalarmin, respectively. Thus, our two best lead compounds (compound 6 & 43) can be considered potent CRF receptor antagonists with binding affinity of 41.0 & 19.2 nM versus 9.7 nM for antalarmin.


Subject(s)
Corticotropin-Releasing Hormone , Receptors, Corticotropin-Releasing Hormone , Pyrimidines/pharmacology
4.
Bioorg Chem ; 115: 105262, 2021 10.
Article in English | MEDLINE | ID: mdl-34411980

ABSTRACT

T-type calcium channels are considered potential drug targets to combat cancer. Combining T-type calcium channel blockers with conventional chemotherapy drugs represents a promising strategy towards successful cancer treatment. From this perspective, we report in this study the design and synthesis of a novel series of N3-sustituted dihydropyrimidines (DHPMs) as anticancer adjuvants to cisplatin (Cis) and etoposide (Eto). Full spectral characterization of the new compounds was done using FT-IR, 1H NMR, 13C NMR, and HRMS. Structure elucidation was confirmed by 2D NMR 1H-H COSY, HSQC and NOESY experiments. Novel derivatives were tested for their Ca2+ channel blocking activity by employing the whole cell patch-clamp technique. Results demonstrated that most compounds were potential T-type calcium channel blockers with the triazole-based C12 and C13 being the most selective agents against CaV3.2 channel. Further electrophysiological studies demonstrated that C12 and C13 inhibited CaV3.2 currents with respective affinity of 2.26 and 1.27 µM, and induced 5 mV hyperpolarizing shifts in the half-inactivation potential. Subsequently, C12 and C13 were evaluated for their anticancer activities alone and in combination with Cis and Eto against A549 and MDA-MB 231 cancer cells. Interestingly, both compounds exhibited potential anticancer effects with IC50 values < 5 µM. Combination studies revealed that both compounds had synergistic effects (combination index CI < 1) on Cis and Eto through induction of apoptosis (p53 activation and up-regulation of BAX and p21 gene expression). Importantly, in silico physicochemical and ADMET assessment of both compounds revealed their potential drug-like properties with decreased risk of cardiac toxicity. Hence, C12 and C13 are promising anticancer adjuvants through inhibition of CaV3.2 T-type calcium channels, thereby serving as eminent leads for further modification.


Subject(s)
Antineoplastic Agents/pharmacology , Calcium Channel Blockers/pharmacology , Calcium Channels, T-Type/metabolism , Cisplatin/pharmacology , Etoposide/pharmacology , Pyrimidines/pharmacology , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Calcium Channel Blockers/chemical synthesis , Calcium Channel Blockers/chemistry , Cell Line, Tumor , Cell Proliferation/drug effects , Cisplatin/chemistry , Dose-Response Relationship, Drug , Drug Screening Assays, Antitumor , Etoposide/chemistry , Humans , Molecular Structure , Pyrimidines/chemical synthesis , Pyrimidines/chemistry , Structure-Activity Relationship
5.
J Child Orthop ; 15(1): 6-11, 2021 Feb 01.
Article in English | MEDLINE | ID: mdl-33643453

ABSTRACT

PURPOSE: To assess the reliability and efficacy of the modified oblique high tibial osteotomy for correction of complex deformity in adolescent tibia vara. METHODS: A total of 19 patients (25 legs) with adolescent tibia vara were enrolled in this study. There were 16 male (84.2%) and three female (15.8%) patients who had modified Rab oblique osteotomy with minimal fixation performed. The age of the patients at time of surgery ranged from 12 years to 30 years (mean 17.23 (sd 5.27)). The body mass index ranged from 22 kg/m2 to 42 kg/m2 (mean 32.05 (sd 6.13)). All patients were followed up for over two years (mean 3.4; 2 to 5). RESULTS: The femoro-tibial angle was improved from -34° to -12° (mean -20.04° (sd 5.24°) preoperatively and from -12° to 7°, postoperatively (mean 2.04° (sd 4.07)). Medial deviation of the mechanical axis corrected from 38 mm to 125 mm (mean 76.13 (sd 23.29)) preoperatively to 0 mm to 36 mm (mean 5.74 (sd 7.3)) postoperatively. The time needed to achieve union ranged from eight weeks to 16 weeks (mean 10.2 (sd 2.42)). According to the Lysholm functional knee score scale, there were 15 excellent (78.9%), two good (10.5%), one fair (5.2%) and one poor (5.2%) after correction of the deformity. CONCLUSION: Modified Rab osteotomy with minimal fixation by two or three screws shows promising results with good correction of varus deformity (coronal plane), internal torsion (axial plane) and procurvatum (sagittal plane), in management of adolescent tibia vara with minimal morbidity and complications. LEVEL OF EVIDENCE: IV.

6.
J Pediatr Orthop B ; 29(6): 550-555, 2020 Nov.
Article in English | MEDLINE | ID: mdl-31856037

ABSTRACT

This systematic review explores the relevant literature to assess the efficacy of the use of arthrodiastasis in the management of Perthes disease. Until this moment, arthrodiastasis is not well established for its use in Perthes disease as opposed to other containment procedures. Furthermore, there are no clear indications for its use in this disease. Twelve articles were matched to the inclusion criteria and all articles were reviewed and radiological and clinical data were collected and compiled. As regards the hip flexion range of motion, the average preoperative flexion range of motion was 55.32°, while the postoperative was 90°. The average preoperative hip abduction range of motion was 12.28° and postoperative was 35.28°. Mean preoperative hip internal rotation range of motion was 8.69° and postoperatively was 24.93°. Mean preoperative external rotation range of motion was 21.73°, while the postoperative range was 33.71°. Final Stulberg classification was ascertained showing most patients ending with stages two and three. Complications were also assessed with most of which being superficial pin tract infections. The use of arthrodiastasis is a valid treatment option for Perthes disease; however, more articles need to be produced showing comparative data of arthrodiastasis versus other containment procedures. Level of evidence - level 1: systematic review.


Subject(s)
Arthrodesis/methods , Disease Management , Legg-Calve-Perthes Disease/surgery , Arthrodesis/trends , Humans , Legg-Calve-Perthes Disease/diagnosis , Orthopedic Procedures/methods , Orthopedic Procedures/trends
7.
Hormones (Athens) ; 18(2): 215-221, 2019 Jun.
Article in English | MEDLINE | ID: mdl-30980254

ABSTRACT

The corticotrophin-releasing factor (CRF) and its type 1 receptor (CRF1R) regulate the hypothalamic-pituitary-adrenal axis, as well as other systems, thus playing a crucial role in the maintenance of homeostasis. Non-peptide CRF1R-selective antagonists exert therapeutic effects on experimental animals with abnormal regulation of their homeostatic mechanisms. However, none of them is as yet in clinical use. In an effort to develop novel small non-peptide CRF1R-selective antagonists, we have synthesized a series of substituted pyrimidines described in a previous study. These small molecules bind to CRF1R, with analog 3 having the highest affinity. Characteristic structural features of analog 3 are a N,N-bis(methoxyethyl)amino group at position 6 and a methyl in the alkythiol group at position 5. Based on the binding profile of analog 3, we selected it in the present study for further pharmacological characterization. The results of this study suggest that analog 3 is a potent CRF1R-selective antagonist, blocking the ability of sauvagine, a CRF-related peptide, to stimulate cAMP accumulation in HEK 293 cells via activation of CRF1R, but not via CRF2R. Moreover, analog 3 blocked sauvagine to stimulate the proliferation of macrophages, further supporting its antagonistic properties. We have also constructed molecular models of CRF1R to examine the interactions of this receptor with analog 3 and antalarmin, a prototype CRF1R-selective non-peptide antagonist, which lacks the characteristic structural features of analog 3. Our data facilitate the design of novel non-peptide CRF1R antagonists for clinical use.


Subject(s)
Anti-Anxiety Agents/chemical synthesis , Antidepressive Agents/chemical synthesis , Pyrimidines/chemistry , Receptors, Corticotropin-Releasing Hormone/antagonists & inhibitors , Amphibian Proteins/chemistry , Amphibian Proteins/pharmacology , Animals , Anti-Anxiety Agents/chemistry , Anti-Anxiety Agents/pharmacology , Antidepressive Agents/chemistry , Antidepressive Agents/pharmacology , Cell Proliferation/drug effects , Drug Design , HEK293 Cells , Humans , Mice , Models, Molecular , Peptide Hormones/chemistry , Peptide Hormones/pharmacology , Pyrimidines/chemical synthesis , Pyrimidines/pharmacology , RAW 264.7 Cells , Structure-Activity Relationship
8.
Bioorg Chem ; 88: 102915, 2019 07.
Article in English | MEDLINE | ID: mdl-31005784

ABSTRACT

Drugs targeting different calcium channel subtypes have strong therapeutic potential for future drug development for cardiovascular disorders, neuropsychiatric diseases and cancer. This study aims to design and synthesize a new series of C2 substituted dihydropyrimidines to mimic the structure features of third generation long acting dihydropyridine calcium channel blockers and dihydropyrimidines analogues. The target compounds have been evaluated as blockers for CaV1.2 and CaV3.2 utilizing the whole-cell patch clamp technique. Among the tested compounds, compound 7a showed moderate calcium channel blockade activity against CaV3.2. Moreover, the predicted physicochemical properties and pharmacokinetic profiles of the target compounds recommend that they can be considered as drug-like candidates. The results highlight some significant information for the future design of lead compounds as calcium channel blockers.


Subject(s)
Calcium Channel Blockers/pharmacology , Calcium Channels, L-Type/metabolism , Calcium Channels, T-Type/metabolism , Pyrimidines/pharmacology , Calcium Channel Blockers/chemical synthesis , Calcium Channel Blockers/pharmacokinetics , Cell Line , Computer Simulation , Drug Design , Electrophysiology/methods , Humans , Patch-Clamp Techniques , Pyrimidines/chemical synthesis , Pyrimidines/pharmacokinetics
9.
Foot Ankle Surg ; 25(4): 469-477, 2019 Aug.
Article in English | MEDLINE | ID: mdl-30321962

ABSTRACT

BACKGROUND: The aim of this study is to compare scarf osteotomy and long chevron osteotomy in treatment of hallux valgus deformity regarding operative time, power of correction and complications. DESIGN: A prospective randomized controlled comparative trial. METHODS: 48 cases with hallux valgus were divided randomly in 2 groups (21 treated by scarf and 22 treated by long chevron osteotomy and 5 were missed during follow up), average age 36 years, follow up time was average of 25.9 months. Patients were assessed clinically, radiologically, and functional scoring system of American College of Foot and ankle Surgeons (ACFAS)was used both pre and postoperatively. RESULTS: Operative time was 69min in scarf group compared to 63min to long chevron group, radiological correction showed no statistically significant difference between both groups while functional improvement in ACFAS score was in favour of long chevron group 69.1% compared to scarf group 57.5% CONCLUSIONS: Both osteotomies possess almost identical corrective power of the IMA (intermetatarsal angle) and similar clinical outcomes with slightly shorter operative time and subjective technical simplicity for the long chevron osteotomy.


Subject(s)
Hallux Valgus/surgery , Osteotomy , Adolescent , Adult , Aged , Female , Hallux Valgus/diagnostic imaging , Humans , Male , Middle Aged , Operative Time , Prospective Studies , Radiography , Treatment Outcome , Young Adult
10.
Bioorg Chem ; 83: 354-366, 2019 03.
Article in English | MEDLINE | ID: mdl-30408648

ABSTRACT

New dihydropyrimidines bearing various lipophilic pharmacophores and functionalities at position 3 were designed and synthesized. The basic framework of the new compounds was designed to maintain the main structural requirements for calcium channel blocking activity of the known dihydropyridines and dihydropyrimidines calcium channel blockers. The newly synthesized compounds were evaluated as antagonists for CaV1.2 and CaV3.2 using the whole-cell patch clamp technique. Seven compounds (4b, 4c, 6c, 9, 13c, 13e and 17b) showed promising dual calcium channel blocking activity and three compounds (13b, 14b and 17a) were selective against Cav3.2. Their drug-likeness has been assessed using Molinspiration and Molsoft softwares. Their physicochemical properties and pharmacokinetic profiles recommend that they can be considered as drug-like candidates.


Subject(s)
Calcium Channel Blockers/pharmacology , Pyrimidines/pharmacology , Animals , Calcium Channel Blockers/chemical synthesis , Calcium Channel Blockers/chemistry , Calcium Channel Blockers/pharmacokinetics , Calcium Channels, L-Type/metabolism , Calcium Channels, T-Type/metabolism , Cell Line , Drug Design , Humans , Molecular Structure , Patch-Clamp Techniques , Pyrimidines/chemical synthesis , Pyrimidines/chemistry , Pyrimidines/pharmacokinetics , Rats , Solubility , Structure-Activity Relationship
11.
Eur J Med Chem ; 138: 900-908, 2017 Sep 29.
Article in English | MEDLINE | ID: mdl-28750312

ABSTRACT

Corticotropin-releasing factor (CRF) is an important neuropeptide hormone which controls the body's overall response to stress. It plays a crucial role in regulating the behavioral, cardiovascular, immune and gastrointestinal systems. Over-activation of the CRF system has been implicated in many disorders including anxiety, depression, drug addiction, hypertension, Irritable Bowel Syndrome (IBS), peptic ulcers, inflammation and others. Thus, binding of CRF to its receptors is an attractive target to develop new medications which aim at treating ailments associated with chronic stress. Numerous small-molecule non-peptide CRF receptor antagonists were developed and many are in various stages in clinical trials. Many showed great promise in treatment of anxiety, depression, peptic ulcers, inflammation, IBS and drug addiction. In our recent previous work, the development of two series of pyrimidine and fused pyrimidine CRF antagonists were described. In continuation of our efforts in this direction, in the current manuscript, the synthesis of a third series of CRF receptor antagonists is described. The binding affinities of select compounds for the type 1 receptor of CRF (CRF1R) were determined and compared to a standard CRF antagonist drug antalarmin. A lead compound was identified and further evaluated by measuring its effect on the inhibition of the agonist-stimulated accumulation of second messengers.


Subject(s)
Corticotropin-Releasing Hormone/antagonists & inhibitors , Thiazoles/pharmacology , Dose-Response Relationship, Drug , HEK293 Cells , Humans , Molecular Structure , Structure-Activity Relationship , Thiazoles/chemical synthesis , Thiazoles/chemistry
12.
Eur J Med Chem ; 134: 52-61, 2017 Jul 07.
Article in English | MEDLINE | ID: mdl-28399450

ABSTRACT

Cardiovascular diseases (CVDs) are the main cause of deaths worldwide. Up-to-date, hypertension is the most significant contributing factor to CVDs. Recent clinical studies recommend calcium channel blockers (CCBs) as effective treatment alone or in combination with other medications. Being the most clinically useful CCBs, 1,4-dihydropyridines (DHPs) attracted great interest in improving potency and selectivity. However, the short plasma half-life which may be attributed to the metabolic oxidation to the pyridine-counterparts is considered as a major limitation for this class. Among the most efficient modifications of the DHP scaffold, is the introduction of biologically active N3-substituted dihydropyrimidine mimics (DHPMs). Again, some potent DHPMs showed only in vitro activity due to first pass effect through hydrolysis and removal of the N3-substitutions. Herein, the synthesis of new N3-substituted DHPMs with various functionalities linked to the DHPM core via two-carbon spacer to guard against possible metabolic inactivation is described. It was designed to keep close structural similarities to clinically efficient DHPs and the reported lead DHPMs analogues, while attempting to improve the pharmacokinetic properties through better metabolic stability. Applying whole batch clamp technique, five compounds showed promising L- and T- type calcium channel blocking activity and were identified as lead compounds. Structure requirements for selectivity against Cav1.2 as well against Cav3.2 are described.


Subject(s)
Calcium Channel Blockers/chemistry , Calcium Channel Blockers/pharmacology , Calcium Channels, L-Type/metabolism , Dihydropyridines/chemistry , Dihydropyridines/pharmacology , Calcium Channel Blockers/chemical synthesis , Crystallography, X-Ray , Dihydropyridines/chemical synthesis , HEK293 Cells , Humans , Hypertension/drug therapy , Models, Molecular
13.
Bioorg Med Chem ; 25(6): 1926-1938, 2017 03 15.
Article in English | MEDLINE | ID: mdl-28233679

ABSTRACT

Low-voltage-activated calcium channels are important regulators of neurotransmission and membrane ion conductance. A plethora of intracellular events rely on their modulation. Accordingly, they are implicated in many disorders including epilepsy, Parkinson's disease, pain and other neurological diseases. Among different subfamilies, T-type calcium channels, and in particular the CaV3.2 isoform, were shown to be involved in nociceptive neurotransmission. The role of CaV3.2 in pain modulation was supported by demonstrating selective antisense oligonucleotide-mediated CaV3.2 knockdown, in vivo antinociceptive effects of T-type blockers, and pain attenuation in CaV3.2 knockout formalin-induced pain model. These Emerging investigations have provided new insights into targeting T-type calcium channels for pain management. Within this scope, various T-type calcium channel blockers have been developed such as mibefradil and ethosuximide. Although being active, most of these molecules interact with other receptors as well. This addresses the need for T-selectivity. Few selective T-type channel blockers of diverse chemical classes were developed such as ABT-639 and TTA-P2. Interestingly, R(-) efonidipine which is a dihydropyridine (DHP) showed T-channel selectivity. Systematic modification of 1,4-dihydropyridine scaffold introduced novel derivatives with 40-fold T-type selectivity over L-type calcium channels. Along these lines, substitution of the DHP core with various analogues favored T-selectivity and may serve as novel pharmacophores. Several dihydropyrimidine (DHPM) mimics were introduced by Squibb as potential candidates. As a continuation of this approach, the current study describes the synthesis of Novel N3 substituted DHPMs with structure similarities to the active DHPs. Different functional groups were introduced to the N3 position through a spacer to gain more information about activity and selectivity. Furthermore, the spacer aims at improving the metabolic stability of the molecules. Initial screening data by whole patch clamp technique showed a robust inhibition of Cav3.2 T-type channels by eleven compounds. Interestingly, four compounds of these were efficient selective T-type blockers. Based on selectivity and efficiency, two compounds were selected for in vivo evaluation in mouse models of inflammatory pain. Results showed effective attenuation of nociception and mechanical hypersensitivity.


Subject(s)
Calcium Channel Blockers/chemical synthesis , Calcium Channel Blockers/pharmacology , Disease Models, Animal , Inflammation/drug therapy , Pain/drug therapy , Animals , Calcium Channel Blockers/chemistry , Male , Mice , Mice, Inbred C57BL , Patch-Clamp Techniques , Proton Magnetic Resonance Spectroscopy
14.
Curr Mol Pharmacol ; 10(4): 270-281, 2017.
Article in English | MEDLINE | ID: mdl-27809751

ABSTRACT

Corticotropin-releasing factor (CRF) can be considered a very important hormone or a chemical mediator. It works closely with other systems to regulate the manner through which the body may respond to stress. Thus it affects many biological processes associated with stress. Dysfunction of this system has also been correlated with various diseases such as major depression, anxiety, drug addiction and eating disorders. Rationally, this means that interfering with binding of CRF to its intended receptors can be an attractive target for drug design aiming at developing new medications for many ailments that are associated with stress such as depression, anxiety and stress-induced relapse in drug addiction. Hundreds of accounts of small molecule antagonists have appeared in the literature and the preclinical and clinical pharmacology have been reported for many of these agents. Several classes of small molecule CRF receptor antagonists which belong to the non-peptide class have been developed with many being widely used for research purposes. Currently several major pharmaceutical companies are pursuing development of small non-peptide CRF1 receptor antagonists. In this review article we explain the importance of development of non-peptide CRF antagonists and their clinical relevance with emphasis on those members that showed great promise or those that were advanced to clinical trials.


Subject(s)
Corticotropin-Releasing Hormone/antagonists & inhibitors , Drug Discovery , Receptors, Corticotropin-Releasing Hormone/antagonists & inhibitors , Small Molecule Libraries/chemistry , Small Molecule Libraries/pharmacology , Animals , Anxiety/drug therapy , Anxiety/metabolism , Corticotropin-Releasing Hormone/metabolism , Depression/drug therapy , Depression/metabolism , Depressive Disorder/drug therapy , Depressive Disorder/metabolism , Drug Discovery/methods , Humans , Molecular Targeted Therapy/methods , Pyridazines/chemistry , Pyridazines/pharmacology , Pyridazines/therapeutic use , Pyrimidines/chemistry , Pyrimidines/pharmacology , Pyrimidines/therapeutic use , Receptors, Corticotropin-Releasing Hormone/metabolism , Small Molecule Libraries/therapeutic use , Substance-Related Disorders/drug therapy , Substance-Related Disorders/metabolism , Thiazoles/chemistry , Thiazoles/pharmacology , Thiazoles/therapeutic use , Triazines/chemistry , Triazines/pharmacology , Triazines/therapeutic use
15.
Eur J Med Chem ; 113: 198-213, 2016 May 04.
Article in English | MEDLINE | ID: mdl-26942627

ABSTRACT

Thiazolo[4,5-d]pyrimidines are fused heterocyclic ring-systems that can be viewed at the first glance as purine isosteres. They are the 7 thia-analogs of purines via the replacement of the nitrogen at position 7 of the purine ring by a sulfur atom. Because of the structural resemblance to adenine and guanine and their related derivatives as adenosine, guanosine, cAMP, cGMP and similar biomolecules, many thiazolo[4,5-d]pyrimidines scaffold were developed and utilized by medicinal chemists to design novel therapeutics. Many were found to have a broad range of pharmacological activities. The outstanding development of thiazolo[4,5-d]pyrimidines within a short time span shows its magnitude of usefulness for medicinal chemistry research. Despite their importance from pharmacological and synthetic point of views, hardly there is a comprehensive review of thiazolo[4,5-d]pyrimidines applications in medicinal research to date. Thus, this review article describes the structures and medicinal significance of all classes of thiazolo[4,5-d]pyrimidines reported in literature to date. It describe the development of thiazolo[4,5-d]pyrimidines as immune-modulators, Corticotropin Releasing Factor (CRF) receptor antagonists, anti-Parkinson's, antiviral, anticancer, antibacterial, antifungal, analgesic, anti-inflammatory agents including COX inhibitors, chemokines antagonists and Fractlkine receptor antagonists.


Subject(s)
Anti-Infective Agents/pharmacology , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Antineoplastic Agents/pharmacology , Antiviral Agents/pharmacology , Drug Discovery , Thiazoles/pharmacology , Anti-Infective Agents/chemical synthesis , Anti-Infective Agents/chemistry , Anti-Inflammatory Agents, Non-Steroidal/chemical synthesis , Anti-Inflammatory Agents, Non-Steroidal/chemistry , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Antiviral Agents/chemical synthesis , Antiviral Agents/chemistry , Chemokines/antagonists & inhibitors , Humans , Molecular Structure , Receptors, Corticotropin-Releasing Hormone/antagonists & inhibitors , Thiazoles/chemical synthesis , Thiazoles/chemistry
16.
Nat Prod Commun ; 9(8): 1143-6, 2014 Aug.
Article in English | MEDLINE | ID: mdl-25233593

ABSTRACT

Three natural cembranoids from the Red Sea soft coral Sarcophyton glaucum namely (1S,2E,4R,6E,8R,11S,12R)-8,12-epoxy-2,6-cembradiene-4,11-diol, (1S,2E,4R,6E,8S,11R,12S)-8,11-epoxy-4,12-epoxy-2,6-cembradiene and (1S,4R,13S)-cembra-2E,7E,11E-trien-4,13-diol were evaluated for their inhibitory effects on mouse melanoma B16F10 cell growth. Results show that all the cembranoids strongly inhibit viability of melanoma cells particularly during 48 -72 hrs treatment and also inhibit de novo DNA synthesis and PARP activity and stimulate fragmentation of DNA. (1S,2E,4R,6E,8R,11S,12R)-8,12-epoxy-2,6-cembradiene-4,11-diol was not cytotoxic to monkey kidney CV-1 cells at the concentration that produces the anti-melanoma effects which indicates that this compound may be a good candidate for further development. (1S,2E,4R,6E,8S,11R,12S)-8,11-epoxy-4,12-epoxy-2,6-cembradiene and (1S,4R,13S)-cembra-2E,7E,11E-trien-4,13-diol were found to be cytotoxic to healthy cells.


Subject(s)
Anthozoa/chemistry , Antineoplastic Agents/pharmacology , Melanoma/drug therapy , Animals , Antineoplastic Agents/chemistry , Cell Line, Tumor , DNA Replication/drug effects , Drug Evaluation, Preclinical , Humans , Indian Ocean , Melanoma/enzymology , Melanoma/genetics , Melanoma/metabolism , Molecular Structure , Poly (ADP-Ribose) Polymerase-1 , Poly(ADP-ribose) Polymerases/genetics , Poly(ADP-ribose) Polymerases/metabolism
17.
Med Chem ; 11(1): 50-9, 2014.
Article in English | MEDLINE | ID: mdl-25059547

ABSTRACT

Corticotropin-releasing factor (CRF) is a neurohormone that plays a crucial role in integrating the body's overall response to stress. It appears necessary and sufficient for the organism to mount functional, physiological and endocrine responses to stressors. CRF is released in response to various triggers such as chronic stress. The role of CRF and its involvement in these neurological disorders suggest that new drugs that can target the CRF function or bind to its receptors may represent a new development of neuropsychiatric medicines to treat various stress-related disorders including depression, anxiety and addictive disorders. Based on pharmacophore of the CRF1 receptor antagonists, a new series of thiazolo[4,5-d] pyrimidines were synthesized as Corticotropin-releasing factor (CRF) receptor modulators and the prepared compounds carry groups shown to produce optimum binding affinity to CRF receptors. Twenty two compounds were evaluated for their CRF1 receptor binding affinity in HEK 293 cell lines and two compounds 5o and 5s showed approximately 25% binding affinity to CRF1 receptors. Selected compounds (5c and 5f) were also evaluated for their effect on expression of genes associated with depression and anxiety disorders such as CRF1, CREB1, MAO-A, SERT, NPY, DatSLC6a3, and DBH and significant upregulation of CRF1 mRNA has been observed with compound 5c.


Subject(s)
Anti-Anxiety Agents/chemistry , Antidepressive Agents/chemistry , Corticotropin-Releasing Hormone/genetics , Pyrimidines/chemistry , Receptors, Corticotropin-Releasing Hormone/chemistry , Thiazoles/chemistry , Anti-Anxiety Agents/chemical synthesis , Anti-Anxiety Agents/pharmacology , Antidepressive Agents/chemical synthesis , Antidepressive Agents/pharmacology , Binding Sites , Corticotropin-Releasing Hormone/metabolism , Cyclic AMP Response Element-Binding Protein/genetics , Cyclic AMP Response Element-Binding Protein/metabolism , Dopamine Plasma Membrane Transport Proteins/genetics , Dopamine Plasma Membrane Transport Proteins/metabolism , Dopamine beta-Hydroxylase/genetics , Dopamine beta-Hydroxylase/metabolism , Gene Expression/drug effects , HEK293 Cells , Humans , Monoamine Oxidase/genetics , Monoamine Oxidase/metabolism , Neuropeptide Y/genetics , Neuropeptide Y/metabolism , Protein Binding , Pyrimidines/chemical synthesis , Pyrimidines/pharmacology , Receptors, Corticotropin-Releasing Hormone/antagonists & inhibitors , Receptors, Corticotropin-Releasing Hormone/genetics , Receptors, Corticotropin-Releasing Hormone/metabolism , Serotonin Plasma Membrane Transport Proteins/genetics , Serotonin Plasma Membrane Transport Proteins/metabolism , Structure-Activity Relationship , Thiazoles/chemical synthesis , Thiazoles/pharmacology
18.
Nat Prod Commun ; 9(2): 151-4, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24689276

ABSTRACT

Three natural cembranoids from the Red Sea soft coral Sarcophyton glaucum namely sarcophine (1), (+)-7alpha,8beta-dihydroxydeepoxysarcophine (2) and sarcophytolide (3) were evaluated for their potential inhibitory effects on growth of mouse melanoma B16F10 cells. Compounds (1) and (2) maximally inhibit viability of melanoma cells during 48 hr and 72 hr treatment at concentrations that show no cytotoxicity on monkey kidney CV-1 cells and also inhibit de novo DNA synthesis and PARP activity. Compound (3) produced cytotoxic effects at the same concentration range it produces its antitumor effects. These data suggest that (1) and (2), but not (3), have potential for further development as antitumor agents against melanoma.


Subject(s)
4-Butyrolactone/analogs & derivatives , Anthozoa/chemistry , Antineoplastic Agents/pharmacology , Diterpenes/pharmacology , Melanoma, Experimental/drug therapy , 4-Butyrolactone/pharmacology , Animals , Cell Line, Tumor , Cell Survival/drug effects , Melanoma, Experimental/pathology , Mice
19.
Eur J Med Chem ; 78: 1-9, 2014 May 06.
Article in English | MEDLINE | ID: mdl-24675175

ABSTRACT

Corticotropin releasing factor (CRF) is a neuropeptide hormone produced from the hypothalamus that controls the secretion of corticotropin (ACTH) from the anterior pituitary gland that, in turn, prompts the adrenal glands to secrete glucocorticoids. This involvement in the hypothalamic-pituitary-adrenal axis (HPA) in response to stress and also playing a key role in behavioral, cardiovascular, immune and gastrointestinal systems made CRF binding to its receptors an important target in drug discovery aiming to develop lead compounds with the potential to treat various stress-related disorders including depression, anxiety and addictive disorders. Several non-peptide CRF1 receptor antagonists were developed by pharmaceutical companies and are currently in clinical trials with the aim of improving the health consequences of chronic stress and for use in the clinical management of anxiety and stress. Many showed promising results not only in treatment of anxiety and depression but also in treatment of CRF-induced hypertension, as well as in treatment of arthritis, irritable bowel syndrome and peptic ulcers. In this manuscript, we describe the synthesis of substituted pyrimidines with close structural similarities to reported lead compounds with promising CRF1 receptor affinities and carrying groups known to be associated with optimum affinity to CRF1 receptors. The affinity of the newly prepared compounds in comparison to antalarmin, a potent CRF1 receptor antagonist in clinical trials as a standard, is also described. Four compounds from the new series showed promising CRF1 receptor affinity.


Subject(s)
Pyrimidines/pharmacology , Receptors, Corticotropin-Releasing Hormone/antagonists & inhibitors , Dose-Response Relationship, Drug , HEK293 Cells , Humans , Ligands , Molecular Structure , Pyrimidines/chemical synthesis , Pyrimidines/chemistry , Receptors, Corticotropin-Releasing Hormone/metabolism , Structure-Activity Relationship
20.
Nat Prod Commun ; 8(2): 153-4, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23513714

ABSTRACT

The cancer chemopreventive potential of sarcophine-diol in a chemical carcinogen initiation-promotion experimental tumor model in mice was evaluated. Sarcophine-diol, when given orally, afforded significant protection in the mouse skin cancer model initiated by the topical administration of (+/-)-(E)-4-methyl-2-[(E)-hydroxyamino]-5-nitro-6-methoxy-3-hexanamide (NOR-1) and promoted by 12-O-tetradecanoylphorbol-13-acetate (TPA). These findings, along with our initial reports, suggest that sarcophine-diol is an effective cancer chemopreventive agent, even when administered orally and at a very low dose and thus indicating possible potential human applications in the control of malignancy.


Subject(s)
Anticarcinogenic Agents/pharmacology , Diterpenes/pharmacology , Hydroxylamines/pharmacology , Skin Neoplasms/prevention & control , Animals , Female , Mice , Mice, Hairless , Tetradecanoylphorbol Acetate
SELECTION OF CITATIONS
SEARCH DETAIL
...